News Orion S.A.

Equities

OEC

LU1092234845

Specialty Chemicals

Real-time Estimate Cboe BZX Other stock markets 13:41:10 2025-12-10 EST			5-day change	1st Jan Change
5.150 ^USD	+4.89%		+0.19%	-67.45%

12-03	Orion Lifts FY25 Outlook on Expectation of Milestone Payment for Prostate Cancer Drug	MT
11-19	Orion S.A. Gains Commercial Traction with Conductive Additives Vital for Grid Modernization	CI

Orion Lifts FY25 Outlook on Expectation of Milestone Payment for Prostate Cancer Drug	12-03	MT
Orion S.A. Gains Commercial Traction with Conductive Additives Vital for Grid Modernization	11-19	CI
Orion SA expands business in conductive additives	11-19	RE
Orion S.A. Gains Commercial Traction With Conductive Additives Vital for Grid Modernization	11-19	BU
TA Associates Reportedly in Frame for Iress Buy	11-07	CI
Orion S.A. Announces CFO Changes, Effective Dec. 1, 2025	11-07	CI
Orion Names Jonathan Puckett CFO	11-07	MT
Orion S.A. names Jonathan Puckett chief financial officer	11-07	RE
Orion S.A. Names Jonathan Puckett Chief Financial Officer	11-07	BU
Orion S.A., Q3 2025 Earnings Call, Nov 05, 2025	11-05
Orion S.A. reports third quarter 2025 financial results	11-04	RE
Tranche Update on Orion S.A.'s Equity Buyback Plan announced on May 5, 2023.	11-04	CI
Orion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	11-04	CI
Orion S.A. Reports Third Quarter 2025 Financial Results	11-04	BU
Orion S.A. Reports Goodwill Impairment for the Third Quarter Ended September 30, 2025	11-04	CI
Stifel Canada Says Healwell's Non-core Divestitures Position it as Pure-play Healthcare SaaS Company	11-04	MT
Orion Updates FY25 Net Sales, Operating Profit Outlook	10-28	MT
Orion Posts Expected Decline in Operating Profit, Narrows Full-Year Forecasts	10-28	FW
Orion Reports Expected Decline in Operating Profit for Q3	10-28	FW
Neinor Homes approves 140 mln euros capital increase	10-23	RE
Alert wrongly tagged to Orion SA withdrawn	10-23	RE
Finland's Orion Obtains Commercial License to Abzena's Cancer Antibody	10-23	MT
Orion Signs Exclusive Licensing Agreement with Abzena for Cancer Antibody	10-23	FW
Orion, Abzena announce exclusive commercial license for Abzena's antibody	10-23	RE
Orion Shares Fall After UBS Downgrade	10-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Orion S.A.

Equities

OEC

LU1092234845

Specialty Chemicals

Filters